Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | TPMT | P51580 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | HCAR3 | P49019 | 7/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28401769 | 0.87 | CASP6 (0.62) | CASP6TSHRLMNACA1CA2 | |
| Hydrochloric Acid SCHEMBL28407796 | 0.85 | CASP6 (0.60) | CASP6TSHRLMNACA1CA2 | |
| SCHEMBL2901128 | 0.84 | VCAM1 (0.48) | CASP6TSHRCA1CA2TPMT | |
| SCHEMBL10756347 | 0.84 | CASP6 (0.55) | CASP6TSHRLMNATPMTALDH1A1 | |
| SCHEMBL8841185 | 0.83 | CASP6 (0.62) | CASP6TSHRLMNATPMTALDH1A1 | |
| SCHEMBL452336 | 0.82 | ALDH1A1 (0.58) | CASP6TSHRLMNATPMTALDH1A1 | |
| SCHEMBL9706244 | 0.82 | TTR (0.62) | CASP6TSHRLMNATPMTALDH1A1 | |
| SCHEMBL27695049 | 0.81 | CA1 (0.47) | CASP6TSHRCA1CA2ALDH1A1 | |
| SCHEMBL2526416 | 0.81 | CA1 (0.47) | CASP6TSHRLMNACA1CA2 | |
| SCHEMBL2894998 | 0.81 | TSHR (0.56) | CASP6TSHRLMNATPMTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132449-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | 1CBIO, INC. | 2024-04-25 | — | — | US | disclosed |
| WO-2024050370-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | 1CBIO, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| US-20100298324-A1 | Prolyl Hydroxylase Inhibitors | SMITH KLINE BEECHAM CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298324-A1 | Prolyl Hydroxylase Inhibitors | SMITH KLINE BEECHAM CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298324-A1 | Prolyl Hydroxylase Inhibitors | SMITH KLINE BEECHAM CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| EP-2240178-A1 | PROLYL HYDROXYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-10-20 | — | — | EP | disclosed |
| WO-2010059549-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010059549-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2009086044-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITH KLINE BEECHAM CORPORATION (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009086044-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITH KLINE BEECHAM CORPORATION (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298324-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | CASP6 3590/4885TSHR 1645/4885LMNA 3880/4885 |
| US-20240132449-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PARP1, PARP11, PARP12 | CASP6 610/4885TSHR 4327/4885LMNA 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.